Information:
Fel:
ID
31915
Beskrivning
A Multiple-dose Study of the Safety and Tolerability of REGN88(SAR153191) in Rheumatoid Arthritis Subjects; ODM derived from: https://clinicaltrials.gov/show/NCT01011959
Länk
https://clinicaltrials.gov/show/NCT01011959
Nyckelord
Versioner (1)
- 2018-10-08 2018-10-08 -
Rättsinnehavare
See clinicaltrials.gov
Uppladdad den
8 oktober 2018
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Rheumatoid Arthritis NCT01011959
Eligibility Rheumatoid Arthritis NCT01011959
- StudyEvent: Eligibility
Similar models
Eligibility Rheumatoid Arthritis NCT01011959
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Rheumatoid Arthritis
Item
patients with an established diagnosis of rheumatoid arthritis
boolean
C0003873 (UMLS CUI [1])
Methotrexate | Methotrexate Dose Stable
Item
patients currently treated with concomitant methotrexate for at least 12 weeks, with a stable dose for at least 6 weeks
boolean
C0025677 (UMLS CUI [1])
C0025677 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0205360 (UMLS CUI [2,3])
C0025677 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0205360 (UMLS CUI [2,3])
Chronic infectious disease Persistent | Communicable Disease
Item
persistent chronic or current active infections
boolean
C0151317 (UMLS CUI [1,1])
C0205322 (UMLS CUI [1,2])
C0009450 (UMLS CUI [2])
C0205322 (UMLS CUI [1,2])
C0009450 (UMLS CUI [2])
anakinra
Item
patients who have taken anakinra within 2 weeks
boolean
C0245109 (UMLS CUI [1])
Etanercept | Cyclosporine | MYCOPHENOLATE | Tacrolimus | Gold | Penicillamine | Sulfasalazine | Hydroxychloroquine
Item
patients who have taken etanercept, cyclosporine, mycophenolate, tacrolimus, gold, penicillamine, sulfasalazine or hydroxychloroquine within 4 weeks
boolean
C0717758 (UMLS CUI [1])
C0010592 (UMLS CUI [2])
C0883242 (UMLS CUI [3])
C0085149 (UMLS CUI [4])
C0018026 (UMLS CUI [5])
C0030817 (UMLS CUI [6])
C0036078 (UMLS CUI [7])
C0699177 (UMLS CUI [8])
C0010592 (UMLS CUI [2])
C0883242 (UMLS CUI [3])
C0085149 (UMLS CUI [4])
C0018026 (UMLS CUI [5])
C0030817 (UMLS CUI [6])
C0036078 (UMLS CUI [7])
C0699177 (UMLS CUI [8])
adalimumab
Item
patients who have taken adalimumab within 6 weeks
boolean
C1122087 (UMLS CUI [1])
abatacept | Azathioprine | Cyclophosphamide | infliximab
Item
patients who have taken abatacept, azathioprine, cyclophosphamide or infliximab within 12 weeks
boolean
C1619966 (UMLS CUI [1])
C0004482 (UMLS CUI [2])
C0010583 (UMLS CUI [3])
C0666743 (UMLS CUI [4])
C0004482 (UMLS CUI [2])
C0010583 (UMLS CUI [3])
C0666743 (UMLS CUI [4])
leflunomide | rituximab
Item
patients who have taken leflunomide or rituximab within 6 months
boolean
C0063041 (UMLS CUI [1])
C0393022 (UMLS CUI [2])
C0393022 (UMLS CUI [2])
tocilizumab | Interleukin-6 Antagonists
Item
patients who have had prior treatment with tocilizumab or any other anti-il-6 medication
boolean
C1609165 (UMLS CUI [1])
C3864925 (UMLS CUI [2])
C3864925 (UMLS CUI [2])
Arthritis Interferes with Evaluation | Other medical condition Interferes with Evaluation
Item
significant arthritis or other medical condition that could interfere with study evaluations
boolean
C0003864 (UMLS CUI [1,1])
C0521102 (UMLS CUI [1,2])
C1261322 (UMLS CUI [1,3])
C3843040 (UMLS CUI [2,1])
C0521102 (UMLS CUI [2,2])
C1261322 (UMLS CUI [2,3])
C0521102 (UMLS CUI [1,2])
C1261322 (UMLS CUI [1,3])
C3843040 (UMLS CUI [2,1])
C0521102 (UMLS CUI [2,2])
C1261322 (UMLS CUI [2,3])
Study Subject Participation Status | Investigational New Drugs
Item
participation in any clinical research study evaluating another investigational drug within 30 days
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
C0013230 (UMLS CUI [2])